Your browser doesn't support javascript.
loading
Delineating the genotypic and phenotypic spectrum of HECW2-related neurodevelopmental disorders.
Acharya, Anushree; Kavus, Haluk; Dunn, Patrick; Nasir, Abdul; Folk, Leandra; Withrow, Kara; Wentzensen, Ingrid M; Ruzhnikov, Maura R Z; Fallot, Camille; Smol, Thomas; Rama, Mélanie; Brown, Kathleen; Whalen, Sandra; Ziegler, Alban; Barth, Magali; Chassevent, Anna; Smith-Hicks, Constance; Afenjar, Alexandra; Courtin, Thomas; Heide, Solveig; Font-Montgomery, Esperanza; Heid, Caleb; Hamm, J Austin; Love, Donald R; Thabet, Farouq; Misra, Vinod K; Cunningham, Mitch; Leal, Suzanne M; Jarvela, Irma; Normand, Elizabeth A; Zou, Fanggeng; Helal, Mayada; Keren, Boris; Torti, Erin; Chung, Wendy K; Schrauwen, Isabelle.
Afiliação
  • Acharya A; Center for Statistical Genetics, Gertrude H. Sergievsky Center and the Department of Neurology, Columbia University Medical Center, New York, New York, USA.
  • Kavus H; Department of Pediatrics, Columbia University, New York, New York, USA.
  • Dunn P; The George Washington University, Washington, District of Columbia, USA.
  • Nasir A; Department of Molecular Science and Technology, Ajou University, Suwon, The Republic of Korea.
  • Folk L; GeneDx, Gaithersburg, Maryland, USA.
  • Withrow K; GeneDx, Gaithersburg, Maryland, USA.
  • Wentzensen IM; GeneDx, Gaithersburg, Maryland, USA.
  • Ruzhnikov MRZ; Neurology and Neurological Sciences, Pediatrics, Division of Medical Genetics, Stanford University and Lucile Packard Children's Hospital, Palo Alto, California, USA.
  • Fallot C; Clinique de Neuropédiatrie, CHU Lille, Lille, France.
  • Smol T; Institut de Génétique, Univ Lille, EA7364 RADEME, CHU Lille, Lille, France.
  • Rama M; Institut de Génétique, CHU Lille, Lille, France.
  • Brown K; Pediatrics-Clinical Genetics and Metabolism, School of Medicine, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
  • Whalen S; UF de génétique Clinique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Assistance Publique-Hôpitaux de Paris (APHP) Sorbonne Université, Hôpital Armand Trousseau, ERN-ITHACA, Paris, France.
  • Ziegler A; Department of Genetics, Angers University Hospital, Angers, France.
  • Barth M; Department of Genetics, Angers University Hospital, Angers, France.
  • Chassevent A; Division of Neurogenetics, Kennedy Krieger Institute, Baltimore, Maryland, USA.
  • Smith-Hicks C; Division of Neurogenetics, Kennedy Krieger Institute, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Afenjar A; Assistance Publique-Hôpitaux de Paris (APHP) Sorbonne Université, Centre de Référence Malformations et maladies congénitales du cervelet et déficiences intellectuelles de causes rares, département de génétique et embryologie médicale, Hôpital Trousseau, Paris, France.
  • Courtin T; Département de génétique, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
  • Heide S; Department of Genetics, Pitié-Salpêtrière Hospital, Referral Center for Intellectual Disabilities of Rare Causes, Assistance Publique-Hôpitaux de Paris (APHP) Sorbonne Université, Paris, France.
  • Font-Montgomery E; University Hospital Medical Genetics Clinic, University of Missouri, Columbia, Missouri, USA.
  • Heid C; University Hospital Medical Genetics Clinic, University of Missouri, Columbia, Missouri, USA.
  • Hamm JA; Pediatric Genetics, East Tennessee Children's Hospital, Knoxville, Tennessee, USA.
  • Love DR; Pathology Genetics, Sidra Medicine, Doha, Qatar.
  • Thabet F; Pediatric Neurology Division, Sidra Medicine, Doha, Qatar.
  • Misra VK; Department of Pediatrics, Division of Genetic, Genomic, and Metabolic Disorders, Children's Hospital of Michigan, Detroit, Michigan, USA.
  • Cunningham M; Discipline of Pediatrics, Central Michigan University, Mount Pleasant, Michigan, USA.
  • Leal SM; Department of Pediatrics, Division of Genetic, Genomic, and Metabolic Disorders, Children's Hospital of Michigan, Detroit, Michigan, USA.
  • Jarvela I; Center for Statistical Genetics, Gertrude H. Sergievsky Center and the Department of Neurology, Columbia University Medical Center, New York, New York, USA.
  • Normand EA; Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, USA.
  • Zou F; Department of Medical Genetics, University of Helsinki, Helsinki, Finland.
  • Helal M; GeneDx, Gaithersburg, Maryland, USA.
  • Keren B; GeneDx, Gaithersburg, Maryland, USA.
  • Torti E; Department of Pediatrics, Columbia University, New York, New York, USA.
  • Chung WK; Département de génétique, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
  • Schrauwen I; GeneDx, Gaithersburg, Maryland, USA.
J Med Genet ; 59(7): 669-677, 2022 07.
Article em En | MEDLINE | ID: mdl-34321324
BACKGROUND: Variants in HECW2 have recently been reported to cause a neurodevelopmental disorder with hypotonia, seizures and impaired language; however, only six variants have been reported and the clinical characteristics have only broadly been defined. METHODS: Molecular and clinical data were collected from clinical and research cohorts. Massive parallel sequencing was performed and identified individuals with a HECW2-related neurodevelopmental disorder. RESULTS: We identified 13 novel missense variants in HECW2 in 22 unpublished cases, of which 18 were confirmed to have a de novo variant. In addition, we reviewed the genotypes and phenotypes of previously reported and new cases with HECW2 variants (n=35 cases). All variants identified are missense, and the majority of likely pathogenic and pathogenic variants are located in or near the C-terminal HECT domain (88.2%). We identified several clustered variants and four recurrent variants (p.(Arg1191Gln);p.(Asn1199Lys);p.(Phe1327Ser);p.(Arg1330Trp)). Two variants, (p.(Arg1191Gln);p.(Arg1330Trp)), accounted for 22.9% and 20% of cases, respectively. Clinical characterisation suggests complete penetrance for hypotonia with or without spasticity (100%), developmental delay/intellectual disability (100%) and developmental language disorder (100%). Other common features are behavioural problems (88.9%), vision problems (83.9%), motor coordination/movement (75%) and gastrointestinal issues (70%). Seizures were present in 61.3% of individuals. Genotype-phenotype analysis shows that HECT domain variants are more frequently associated with cortical visual impairment and gastrointestinal issues. Seizures were only observed in individuals with variants in or near the HECT domain. CONCLUSION: We provide a comprehensive review and expansion of the genotypic and phenotypic spectrum of HECW2 disorders, aiding future molecular and clinical diagnosis and management.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ubiquitina-Proteína Ligases / Transtornos do Neurodesenvolvimento / Deficiência Intelectual Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Med Genet Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ubiquitina-Proteína Ligases / Transtornos do Neurodesenvolvimento / Deficiência Intelectual Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Med Genet Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos